This past spring, many provider organizations received notice of a yet another regulatory compliance assessment as part of their HIPAA accountability checklist.
The Department of Health and Human Services, Office for Civil Rights (OCR) announced the start of the Phase 2 HIPAA Audit Program to ensure that “policies and procedures adopted by covered entities and their business associates meet selected standards and implementation specifications of the Privacy, Security, and Breach Notification Rules.” Indianapolis-based Eskenazi Health, one of the largest safety net health systems, was one of those organizations.
The deadline for Class II medical devices passed last month, and with Class III devices, all implantables regardless of class, and now Class II devices covered by the UDI regulation, more than 50 percent of devices sold in the United States should be labelled with unique device identifiers (UDI). However, a considerable number of manufacturers are still struggling to fully comply with the rule or create a sustainable process for ongoing compliance. Some may not have even begun the process. The final UDI ruling was published in September of 2013. With three years to prepare and several deadlines already passed, what is standing in the way of manufacturers? It turns out there is more than one reason many manufacturers haven’t completed their initial submissions to the FDA’s Global UDI Database (GUDID).
Healthcare manufacturers are asking the questions – Where do we go next? What’s happening in the market? Are there unidentified growth opportunities? The right data helps you answer those questions and evaluate sales performance in order to get ahead. We took a look at how one of our medical products manufacturing companies is using GHX Market Intelligence to fuel growth.
Following is a brief overview of how one medical products manufacturing company fueled market growth using GHX Market Intelligence
Since 2013, Mount Sinai Health System has grown rapidly through M&A activity. As a result, we’ve had multiple hospitals with their own supply chain and accounts payable (AP) departments each using disparate technologies, including different enterprise resource planning (ERP) systems and item masters.
As my friends know (and my poor husband must deal with), I am currently studying statistics in grad school. In the midst of the occasional (okay not always so occasional) challenge of a new theorem or mathematical formula, I have gained a new appreciation for the concept of uncertainty, which is what statistically significant research tries to reduce, while recognizing that it can never be completely eliminated.
Most healthcare industry challenges are not one sided. The challenges are felt by both providers and suppliers, paper invoicing being a good example. There are the tangible costs in postage, ink, time to receive mail, to open mail, remove exceptions and route for approval. Then there is the invoice mystery- did the customer receive the invoice and is it ready for payment?